Cannabinoid pharmacology: The first 66 years

British Journal of Pharmacology

Volumn 147, Issue SUPPL. 1, 2006, Pages

  Pertwee, Roger G ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

2 arachidonoyl glycerol; Anandamide; Autoimpairment; Autoprotection; Cannabinoid receptor agonists; Cannabinoid receptor antagonists; Cannabinoids; Cannabis; Endocannabinoids

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N MORPHOLINO 1H PYRAZOLE 3 CARBOXAMIDE; 2 ARACHIDONOYLGLYCEROL; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 4 [6 METHOXY 2 (4 METHOXYPHENYL) 3 BENZOFURANYLCARBONYL]BENZONITRILE; 5 (1,1 DIMETHYLHEPTYL) 2 (3 HYDROXY 7 HYDROXYMETHYLDECAHYDRO 1 NAPHTHYL)PHENOL; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; ANANDAMIDE; BAY 38 7271; CANNABIDIOL; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR AGONIST; CANNABINOID RECEPTOR ANTAGONIST; CANNABINOL; CANNABIS; DELTA8 TETRAHYDROCANNABINOL; DEXANABINOL; DRONABINOL; NABILONE; O 1057; RIMONABANT; TETRAHYDROCANNABINOL; UNCLASSIFIED DRUG;

BIOASSAY; BLOOD BRAIN BARRIER; CANCER; DRUG ACTIVITY; DRUG DEPENDENCE; DRUG STRUCTURE; DRUG TOLERABILITY; ENTEROPATHY; HUMAN; MULTIPLE SCLEROSIS; MYENTERIC PLEXUS; NONHUMAN; PRIORITY JOURNAL; REVIEW; STATISTICAL SIGNIFICANCE; STRUCTURE ACTIVITY RELATION;

ANIMALS; CANNABINOIDS; DRUG TOLERANCE; ENDOCANNABINOIDS; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; LIGANDS; RECEPTORS, CANNABINOID;

EID: 30444457225     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0706406     Document Type: Review

References (40)

1. 1-tetrahydrocannabinol and other cannabinoids with emphasis on man. Pharmacol. Rev., 38, 21-43.
2. BROWN, A. & WISE, A. (2003). Identification of modulators of gpr55 activity. US Patent Document Number 20030113814 at http://appft1.uspto.gov/ netahtml/PTO/search-bool.html.
3. DEVANE, W.A., HANUS, L., BREUER, A., PERTWEE, R.G., STEVENSON, L.A., GRIFFIN, G., GIBSON, D., MANDELBAUM, A., ETINGER, A. & MECHOULAM, R. (1992). Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science, 258, 1946-1949.
4. DI MARZO, V., DE PETROCELLIS, L. & BISOGNO, T. (2005). The biosynthesis, fate and pharmacological properties of endocannabinoids. In: Cannabinoids. Handbook of Experimental Pharmacology. ed. Pertwee, R.G. vol. 168, pp. 147-185. Heidelburg: Springer-Verlag.
5. ELSOHLY, M.A. (2002). Chemical constituents of cannabis. In: Cannabis and Cannabinoids. Pharmacology, Toxicology and Therapeutic Potential. eds. Grotenhermen, F. & Russo, E. pp. 27-36. New York: Haworth Press Inc.
6. GILL, E.W., PATON, W.D.M. & PERTWEE, R.G. (1970). Preliminary experiments on the chemistry and pharmacology of cannabis. Nature, 228, 134-136.
7. HAAGEN-SMIT, A.J., WAWRA, C.Z., KOEPFLI, J.B., ALLES, G.A., FEIGEN, G.A. & PRATER, A.N. (1940). A physiologically active principle from Cannabis sativa (marihuana). Science, 91, 602-603.
8. HILLARD, C.J. & JARRAHIAN, A. (2003). Cellular accumulation of anandamide: consensus and controversy. Br. J. Pharmacol., 140, 802-808.
9. HOWLETT, A.C. (2005). Cannabinoid receptor signaling. In: Cannabinoids. Handbook of Experimental Pharmacology, ed. Pertwee, R.G. vol. 168, pp. 53-79. Heidelburg: Springer-Verlag.
10. HOWLETT, A.C., BARTH, F., BONNER, T.I., CABRAL, G., CASELLAS, P., DEVANE, W.A., FELDER, C.C., HERKENHAM, M., MACKIE, K., MARTIN, B.R., MECHOULAM, R. & PERTWEE, R.G. (2002). International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol. Rev., 54, 161-202.
11. LOEWE, S. (1944). Studies on the pharmacology of marihuana. In: The Marihuana Problems in the City of New York, ed. The Mayor's Committee on Marihuana. pp. 149-212. Lancaster, PA: The Jaques Cattell Press.
12. LOEWE, S. (1946). Studies on the pharmacology and acute toxicity of compounds with marihuana activity. J. Pharmacol. Exp. Ther., 88, 154-161.
13. MECHOULAM, R. (1973). Cannabinoid chemistry. In: Marijuana, ed. Mechoulam, R. pp. 1-99. New York: Academic Press.
14. MECHOULAM, R. (1986). The pharmacohistory of Cannabis sativa. In: Cannabinoids as Therapeutic Agents, ed. Mechoulam, R. pp. 1-19. Boca Raton, FL: CRC Press.
15. MECHOULAM, R. & HANUS, L. (2000). A historical overview of chemical research on cannabinoids. Chem. Phys. Lipids, 108, 1-13.
16. PATON, W.D.M. & PERTWEE, R.G. (1972). Effect of cannabis and certain of its constituents on pentobarbitone sleeping time and phenazone metabolism. Br. J. Pharmacol., 44, 250-261.
17. PATON, W.D.M. & PERTWEE, R.G. (1973a). The pharmacology of cannabis in animals. In: Marijuana, ed. Mechoulam, R. pp. 191-285. New York: Academic Press.
18. PATON, W.D.M. & PERTWEE, R.G. (1973b). The actions of cannabis in man. In: Marijuana, ed. Mechoulam, R. pp. 287-333. New York: Academic Press.
19. PERTWEE, R.G. (1972). The ring test: a quantitative method for assessing the 'cataleptic' effect of cannabis in mice. Br. J. Pharmacol., 46, 753-763.
20. PERTWEE, R.G. (1988). The central neuropharmacology of psychotropic cannabinoids. Pharmacol. Ther., 36, 189-261.
21. PERTWEE, R.G. (1991). Tolerance to and dependence on psychotropic cannabinoids. In: The Biological Bases of Drug Tolerance and Dependence, ed. Pratt, J.A. pp. 231-263. London: Academic Press.
22. 2 receptors. Pharmacol. Ther., 74, 129-180.
23. PERTWEE, R.G. (1999). Pharmacology of cannabinoid receptor ligands. Curr. Med. Chem., 6, 635-664.
24. PERTWEE, R.G. (2004). The pharmacology and therapeutic potential of cannabidiol. In: Cannabinoids, ed. Di Marzo, V. pp. 32-83. New York: Kluwer Academic/Plenum Publishers.
25. 1 receptors. Life Sci., 76, 1307-1324.
26. PERTWEE, R.G. (2005b). Pharmacological actions of cannabinoids. In: Cannabinoids. Handbook of Experimental Pharmacology. ed. Pertwee, R.G. vol. 168, pp. 1-51. Heidelburg: Springer-Verlag.
27. PERTWEE, R.G. (2005c). The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids. AAPS J. (in press).
28. PERTWEE, R.G., FERNANDO, S.R., GRIFFIN, G., ABADJI, V. & MAKRIYANNIS, A. (1995). Effect of phenylmethylsulphonyl fluoride on the potency of anandamide as an inhibitor of electrically evoked contractions in two isolated tissue preparations. Eur. J. Pharmacol., 272, 73-78.
29. PERTWEE, R.G., GIBSON, T.M., STEVENSON, L.A., ROSS, R.A., BANNER, W.K., SAHA, B., RAZDAN, R.K. & MARTIN, B.R. (2000). O-1057, a potent water-soluble cannabinoid receptor agonist with antinociceptive properties. Br. J. Pharmacol., 129, 1577-1584.
30. PERTWEE, R.G., STEVENSON, L.A. & GRIFFIN, G. (1993). Cross-tolerance between delta-9-tetrahydrocannabinol and the cannabimimetic agents, CP 55,940, WIN 55,212-2 and anandamide. Br. J. Pharmacol., 110, 1483-1490.
31. 1 receptor. Mol. Pharmacol., 68, 1484-1495. http://molpharm.aspetjournals.org/cgi/content/ abstract/mol.105.016162v1.
32. RINALDI-CARMONA, M., BARTH, F., HÉAULME, M., SHIRE, D., CALANDRA, B., CONGY, C., MARTINEZ, S., MARUANI, J., NÉLIAT, G., CAPUT, D., FERRARA, P., SOUBRIE, P., BRELIÈRE, J.C. & LE FUR, G. (1994). SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett., 350, 240-244.
33. ROBSON, P. (2005). Human studies of cannabinoids and medicinal cannabis. In: Cannabinoids. Handbook of Experimental Pharmacology, ed. Pertwee, R.G. vol. 168, pp. 719-756. Heidelburg: Springer-Verlag.
34. ROSS, R.A. (2003). Anandamide and vanilloid TRPV1 receptors. Br. J. Pharmacol., 140, 790-801.
35. SIM-SELLEY, L.J. (2003). Regulation of cannabinoid CB1 receptors in the central nervous system by chronic cannabinoids. Crit. Rev. Neurobiol., 15, 91-119.
36. TANDA, G. & GOLDBERG, S.R. (2003). Cannabinoids: reward, dependence, and underlying neurochemical mechanisms - a review of recent preclinical data. Psychopharmacology, 169, 115-134.
37. 2 receptor antagonist. Br. J. Pharmacol., Epub 3 October 2005; doi:10.1038/sj.bjp.0706414.
38. VAN GAAL, L.F., RISSANEN, A.M., SCHEEN, A.J., ZIEGLER, O. & ROSSNER, S. (2005). Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet, 365, 1389-1397.
39. VAUGHAN, C.W. & CHRISTIE, M.J. (2005). Retrograde signalling by endocannabinoids. In: Cannabinoids. Handbook of Experimental Pharmacology, ed. Pertwee, R.G. vol. 168, pp. 367-383. Heidelburg: Springer-Verlag.
40. WALKER, J.M. & HOHMANN, A.G. (2005). Cannabinoid mechanisms of pain suppression. In: Cannabinoids. Handbook of Experimental Pharmacology, ed. Pertwee, R.G. vol. 168, pp. 509-554. Heidelburg: Springer-Verlag.